Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezpeg in severe to very severe alopecia areata (Rezolve AA)
2023-509981-39-00Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Rezpegaldesleukin arm with Placebo arm (2 arms). Primary endpoint: Percent change from baseline in SALT score at Week 36. Started Nov 2024; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2023-509981-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509981-39-00.